Background: Residual renal function (RRF) affects the survival rate and the development of cardiovascular disease in peritoneal dialysis (PD) patients. We evaluated the impact of RRF on oxidative and carbonyl stress in PD patients. Methods: Plasma advanced oxidation protein products (AOPP) and pentosidine were measured in PD patients with a urine volume of ≥300 ml/day (group A, n = 17) and <300 ml/day (group B, n = 14). AOPP and pentosidine were reevaluated after 12 months of follow-up in group A. Results: Plasma levels of AOPP and pentosidine in group A were significantly lower than those in group B. Renal creatinine clearance was inversely correlated with AOPP (p < 0.05) and pentosidine (p < 0.01). After 12 months of follow-up, no significant change was observed in AOPP and pentosidine in groups who maintained a urine volume of ≥300 ml/day, but significantly increased in groups whose urine volume decreased to less than 300 ml/day. There were significant inverse relationships between the changes in renal creatinine clearance and AOPP (p < 0.01) and pentosidine (p < 0.05). Conclusion: Loss of RRF is associated with increased plasma AOPP and pentosidine, indicating that preservation of RRF has a beneficial effect in reducing the oxidative and carbonyl stress in PD patients.

1.
Bargman JM, Thorpe KE, Churchill DN, for the CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158–2162.
2.
Rocco MV, Frankenfield DL, Prowant B, Frederick P, Flanigan MJ: Risk factors for early mortality in US peritoneal dialysis patients: impact of residual renal function. Pert Dial Int 2002;22:371–379.
3.
Termoeschulzen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Kredit RT, for the NECOSAD Study Group: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003;41:1293–1302.
4.
Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui S, Li PK: Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005;20:396–403.
5.
Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, for the Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective randomized, controlled trial. J Am Soc Nephrol 2002;13:1307–1320.
6.
Szeto C, Wong TY, Leung C, Wang AY, Law M, Lui S, Li PK: Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000;58:400–407.
7.
Szeto C, Wong TY, Chow K, Leung C, Li PK: Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003;18:977–982.
8.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS, on behalf of the CREED investigators: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001;12:2768–2774.
9.
Wang AY, Wang M, Woo J, Law M, Chow K, Li PK, Lui SF, Sanderson JE: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002;62:639–647.
10.
Wang AY, Wang M, Woo J, Lam CW, Lui S, Li PK, Sanderson JE: Inflammation, residual renal function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186–2194.
11.
Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170–1181.
12.
Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2004;45:39–47.
13.
Peppa M, Uribarri J, Cai W, Lu M, Vlassara H: Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004;43:690–695.
14.
Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524–2532.
15.
Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212–2217.
16.
Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Bárány P, Heimbürger O, Lindholm B: Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006;66:418–425.
17.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304–1313.
18.
Suliman ME, Heimbürger O, Bárány P, Anderstam B, Pecoits-Filho R, Ayala ER, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003;14:1614–1622.
19.
Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunie M, Verger C, Jungers P, Descamps-Latscha B: The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 1996;45:379–382.
20.
Zoccali C, Mallamaci F, Asahi K, Benedetto FA, Tripepi G, Tripepi R, Nicocia G, Buemi M, Miyata T: Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 2001;14:293–298.
21.
Randerson DH, Chapman GV, Farrell PC: Amino acid and dietary status in CAPD patients; in Atkins RC, Farrell PC, Thomson N (eds): Peritoneal Dialysis. Edinburgh, Churchill-Livingstone, 1981, pp 180–191.
22.
Takahashi M, Hoshino H, Kushida K, Kawano K, Inoue T: Direct quantification of pentosidine in urine and serum by HPLC with column switching. Clin Chem 1996;42:1439–1444.
23.
Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, van Ypersele de Strihou C, Kurokawa K: Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998;53:416–422.
24.
Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, van Ypersele de Strihou C, Miyata T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of ‘carbonyl stress’. Kidney Int 1999;55:2478–2492.
25.
Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005;46:512–519.
26.
Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G, for the HEMO Study Group: Serum β-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO Study. J Am Soc Nephrol 2006;17:546–555.
27.
Shinkai S, Chaves PHM, Fujiwara Y, Watanabe S, Shibata H, Yoshida H, Suzuki T: β2-Microglobulin for risk stratification of total mortality in the elderly population. Arch Intern Med 2008;168:200–206.
28.
Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212–1218.
29.
Slowik-Zylka D, Safranow K, Dziedziejko V, Dutkiewicz G, Ciechanowaski C, Chlubek D: The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients. J Nephrol 2006;19:65–69.
30.
Motomiya Y, Oyama N, Iwamoto H, Uchimura T, Maruyama I: Nε-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. Kidney Int 1998;54:1357–1366.
31.
Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002;346:1954–1962.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.